Event Photos-1
Event Photos-2
Event Photos-3
Event Photos-4
Event Photos-5
Signing Ceremony of "Cancer Precision Medicine and Biobank Consortium Cooperation Pilot Project" on March 4, 2021
In order to promote personalized precision medicine to benefit Taiwan’s cancer patients, and to consolidate Taiwan’s leading position in personalized precision medicine in the world, the National Health Institute and Roche Pharmaceuticals signed a memorandum of cooperation on November 14, 2019. Under this basis, Ministry of Health and Welfare, National Health Research Institutes and Roche Pharmaceuticals agreed to further develop a cooperative relationship and jointly promote the "Cancer Precision Medicine and Biobank Consortium Cooperation Pilot Project" to promote cancer precision medicine and provide best treatment strategies and opportunities for cancer patients in Taiwan and accelerate the establishment of National Biobank Consortium of Taiwan （NBCT） and enhance its leading position in the global personalized precision medicine.
As of May 2021, Taiwan already has 35 Biobanks being approved by the Ministry of Health and Welfare. Since Taiwan has the "Biobank management act", it is possible to legally obtain broad consent from participants to use their specimens and medical information and to link with other domestic databases. This law also has strict personal information protection through regulations, as well as commercial benefit feedback. Thus, Biobank can not only provide high-quality medical information and specimens for academic use, but also the industry for commercial use legally. This is the biggest niche of the biobanks in Taiwan.
Through the cooperation of all biobanks in Taiwan, with uniform quality standards and clinical data content, a large and comprehensive human biobank network can be quickly established. Under such design, National Biobank Consortium of Taiwan （NBCT） was established through the fund support and governance from the government. All Alliance will follow the same SOP for the biomaterial collection and have the same quality of the biosample when submitted to the applicants.
Adequate and consistent clinical data will also be established under well information security management. Since the contents of the biobanks from different institute are quite different, NBCT is able to quickly establish a large and comprehensive biobank network. Currently NBCT already successfully invited 30 biobanks to join and has more than 420 thousands participants with various kinds of biosamples available for applicants.
This Biobank Consortium will also pay intention to the value-added services to further increase the importance of this biobank network, further expanding the database in this biobank consortium. Our goal is to build a huge and comprehensive biomedical big data network research, in line with the needs of biotechnology pharmaceutical, artificial intelligence, auxiliary medical and other industries
related News